Background {#Sec1}
==========

Patients with Atrial fibrillation (AF) have a higher risk for stroke or systemic embolism, death and disability \[[@CR1]\]. Oral anticoagulants, either vitamin K antagonist (VKA) or direct oral anticoagulants (DOACs) reduce that thromboembolic risk by about two-thirds irrespective of baseline risk \[[@CR2]\]. However, the use of anticoagulation is associated with increased risk of bleeding, with intracranial hemorrhage (ICH) being the most serious bleeding complication \[[@CR3]\]. Randomized controlled trials (RCT) of DOACs \[Dabigatran, Rivaroxaban, Apixaban, and Edoxaban\] have demonstrated similar protection against ischemic stroke but lower rates of ICH compared with VKAs \[[@CR4]--[@CR7]\].

The RCTs of DOACs in AF patients used dose adjustments based on patient characteristics such age, weight, renal function and the use of concomitant medications. A reduced dose of 75 mg twice daily of dabigatran is recommended to decrease bleeding risk in patients with creatinine clearance (CrCl) 15--30 mL/minute, or co- administration of a strong P-glycoprotein \[P-gp\] inhibitor (e.g., dronedarone) in patients with CrCl 30--50 mL/minute \[[@CR8], [@CR9]\]. With regards to rivaroxaban, a dose reduction to 15 mg daily is recommended in patients with CrCl 15--50 mL/minute, and concomitant use of a dual P-gp and cytochrome-3A4 \[P-gp-Cyp3A4\] inhibitor should be avoided to prevent potential increased rivaroxaban concentration \[[@CR10]\]. Administration of lower apixaban dose 2.5 mg twice daily is indicated if 2 of the following 3 criteria are met: age \> 80 years, weight \< than 60 kg, and serum Creatinine \> 1.5 mg/dl \[[@CR11]\].

Since the use of DOACs became widespread, deviations from the recommended dosing are not infrequent \[[@CR12], [@CR13]\]. Analysis of 5738 patients treated with DOACs from the ORBITA-AF II registry showed that 9.4% of patients were under-dosed and 3.4% were overdosed. Overdosing was associated with significantly increased all-cause mortality whereas under-dosing was associated with increased cardiovascular hospitalizations \[[@CR14]\]. A subsequent analysis of 7925 AF patients treated with DOACs from the same registry showed that 16% of patients were on reduced doses with many of these doses adjustments (57%) not following the recommended doses \[[@CR15]\]. Nevertheless, after risk- adjustment, the use of lower-than-recommended dose resulted in similar thromboembolic and bleeding risk compared to appropriately dosed DOAC use \[[@CR15]\].

We hypothesized that a sizeable number of DOAC prescriptions do not adhere to the Food and Drug Administration (FDA) dosing criteria and may increase thromboembolic and bleeding events. The purpose of our study was to: 1) examine characteristics and predictors of low dose use among patients who meet FDA criteria for standard dose, or standard dose use among patients who meet FDA criteria for low dose, among patients who initiate dabigatran and rivaroxaban, ii) compare the risk of ischemic stroke and bleeding events in patients receiving off-label low dose or off-label standard dose to patients receiving FDA-recommended doses in a community-based sample of elderly Medicare beneficiaries with AF enrolled in a large U.S. health plan.

Methods {#Sec2}
=======

Data source {#Sec3}
-----------

We designed a new user retrospective cohort study using data for Medicare beneficiaries enrolled in a large U.S. health plan with prescription drug coverage. Medical (inpatient visit, outpatient physician visits) and pharmacy claims with detailed prescription fill information from October 1, 2010 through December 31, 2016 were analyzed. In addition, the data also includes laboratory test results (such as serum creatinine) for Medicare beneficiaries enrolled in managed care plans. The study was non-human subject research by the University of Iowa institutional review board because it involved analysis of an existing database that was fully de-identified.

Patient population {#Sec4}
------------------

We analyzed claims for Medicare beneficiaries age \> = 65 years with newly diagnosed atrial fibrillation (AF) between 2010 and 2016 (dabigatran was approved by FDA in October 2010 followed by rivaroxaban approval in November 2011). We identified patients who initiated dabigatran 150 mg twice daily (standard dose) or 75 mg twice daily (low dose), or rivaroxaban 20 mg daily (standard dose) or 15 mg daily. We did not include patients receiving apixaban as information to assess dosing criteria such as patient weight was not available in our data, and we did not include patients receiving edoxaban due to relatively low use of this drug during our time frame. Patients were categorized into mutually exclusive groups according to the first DOAC and DOAC dose received.

Patients were excluded if they did not have a diagnosis of AF during the 12 months prior to initiating the DOAC, where AF was defined as International Classification of Diseases--Ninth Revision--Clinical Modification \[ICD-9-CM\] code 427.31 or ICD-Tenth Revision \[ICD-10\] code I48.0, I48.1, I48.2, I48.3, I48.4, or I48.91, as primary or secondary diagnosis. Additionally, we excluded patients who: i) were younger than 65 years at the time of diagnosis, ii) had a diagnosis indicating pulmonary embolism or deep vein thrombosis within 8 weeks prior to initiating the DOAC, iii) underwent hip surgery within 6 weeks prior to initiating the DOAC, or iv) were not enrolled in the health care plan for at least 1 year prior to initiating the DOAC.

Patients who initiated dabigatran or rivaroxaban were categorized to approximate dosing criteria, using the most recent estimated glomerular filtration rate (eGFR) available prior to initiating the DOAC as a proxy for creatinine clearance. eGFR was calculated based on Modification of Diet in Renal Disease (MDRD) Study equation or Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation \[[@CR16], [@CR17]\]. Patients who received dabigatran were deemed to meet criteria for low dose if they had severe renal disease (defined as eGFR \< 30 mL/minute/ 1.73 m2) or had moderate renal disease and concurrent use of a p-gp inhibitor (where moderate renal disease was defined as eGFR 30--50 mL/minute/1.73 m2 and p-gp inhibitors included dronedarone, cyclosporine, itraconazole, tacrolimus, ketoconazole). Patients who received rivaroxaban were deemed to meet criteria for low dose if they had eGFR\< 50 or concomitant use of a dual P-gp-Cyp3A4 inhibitor (including ketoconazole, fluconazole, itraconazole, cobicistat, conivaptan, indinavir, voriconazole, posaconazole, nefazodone HCL, ritonavir, saquinavir, telithromycin). Patients with no valid GFR for assessing renal function were excluded. Among patients eligible for low doses of dabigatran or rivaroxaban, 87.4 and 86.5% had available eGFR whereas among those eligible for standard dose dabigatran or rivaroxaban, 54.9 and 56% had available eGFR respectively. We performed sensitivity analysis for DOAC dose adjustments based on eGFR only, excluding drug interactions.

Covariates {#Sec5}
----------

Data on patient-level characteristics such as demographics, comorbid conditions, concurrent medication use, and prior health services utilization were extracted from health care plan enrollment data and inpatient, outpatient, and physician claims. Comorbid diseases were identified by ICD-9-CM/ICD-10 diagnoses on claims during the 12 months preceding the date of first DOAC fill. We used the Charlson Comorbidity Index to estimate patients' overall comorbidity status \[[@CR18]\]. We also identified all conditions in the CHA2DS2-VASc stroke risk score (congestive heart failure diagnosis, female sex, hypertension diagnosis, diabetes, age, prior stroke or transient ischemic attack, and vascular disease diagnosis). History of major bleeding was defined as any prior major bleeding, gastrointestinal bleeding, intracranial hemorrhage, or prior receipt of transfusion. Additional conditions included liver disease, alcohol abuse, obesity, chronic obstructive pulmonary disease, peripheral vascular disease, pulmonary circulation disease, heart valve disease, history of coronary revascularization, history of implantable cardiac device, and prior pulmonary embolism or deep vein thrombosis. We also extracted data on medication use at the time of DOAC initiation (p-glycoprotein inhibitors, cytochrome 3A4 inhibitors, insulin, statins, beta blockers, angiotensin-converting-enzyme (ACE) inhibitors, angiotensin-receptor blockers (ARBs), calcium channel blockers, prescription antiplatelets (e.g., clopidogrel), proton pump inhibitors and non-steroidal anti-inflammatory drugs. (A list of included drugs and ICD9/ICD10 codes for comorbid conditions is provided in Additional file [1](#MOESM1){ref-type="media"}: Table S1). Medications were considered concomitant if the patient had supply within 90 days from the DOAC prescription. We also identified patients with a history of warfarin use prior to initiating the DOAC.

Endpoints {#Sec6}
---------

We selected the following clinical endpoints: i) ischemic stroke, ii) any major bleeding, iii) gastrointestinal bleeding (GI), iv) intracranial bleeding based on the primary ICD-9-CM/ICD-10 diagnosis on inpatient claims for acute care stays (definitions provided in Additional file [1](#MOESM1){ref-type="media"}: Table S1). We also examined drug discontinuation, as defined by the date of last fill for the original DOAC and dose. Patients were followed from the date of the initial DOAC prescription until December 31, 2016 or lapse of health plan enrollment (due to death or other reason), or cessation of the initial DOAC dose.

Statistical analysis {#Sec7}
--------------------

Analyses were conducted separately for patients who initiated dabigatran and rivaroxaban, and by dose eligibility. For example, among patients who received dabigatran and met criteria for low dose dabigatran, we compared characteristics and outcomes among patients who received standard dose in contrast to dosing criteria vs. those who received the recommended low dose. Similarly, among patients who received dabigatran and met criteria for standard dose, we compared patients who received low dose vs. those who received the recommended standard dose. We compared demographic characteristics, comorbid diseases, and concurrent medication use among patients on different doses using the chi-square test.

We examined rates of ischemic stroke, any major bleeding, GI hemorrhage, and intracranial hemorrhage per patient-year of follow-up in the full sample and in propensity matched patients. Specifically, we performed 2-way nearest-neighbor propensity-matching to create groups of patients receiving low dose or standard dose that were balanced with respect to observed patient characteristics. Propensity matching was conducted separately for patients qualifying for low or standard dose, and for patients on dabigatran or rivaroxaban (i.e., four separate propensity matched samples). We assessed covariate balance in propensity-matched samples using standardized differences between patients receiving low or standard dose, where differences less than 10% indicate satisfactory balance. Because standardized differences remained greater than 10% for a small number of covariates, we further adjusted for unbalanced covariates if they were related to the outcome of interest using Cox proportional hazards regression models. We then calculated rates of each endpoint per patient year of follow-up in unmatched and propensity-matched samples. Statistical significance was assessed using Cox proportional hazards regression models that censored for end of follow-up (December 31, 2016), medication cessation, or disenrollment from the managed care plan for any reason. Results were reported as hazard ratios (HR) with 95% confidence intervals (CI) for each drug and recommended dose, where the HR reflects the outcome rate for off-label dosing relative to FDA-recommended dose. Finally, one sensitivity analysis was performed in which drug dosing criteria was based on GFR measurements only, without considering pharmacologic interactions reflected in FDA criteria.

All analyses were conducted using SAS with 2-tailed level of significance set at 0.05.

Results {#Sec8}
=======

Patient characteristic {#Sec9}
----------------------

We identified 8035 patients with valid GFR measurements including 6580 on standard dabigatran dose and 1455 patients on low dose (18.1%); 19,712 patients were rivaroxaban including 13,245 on standard dose rivaroxaban and 6467 on low dose (32.8%). We identified significant differences in baseline characteristics between different does of dabigatran and rivaroxaban before propensity matching (Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}). Among dabigatran patients, those taking low dose were more likely to be over 75 years (*P* \< 0.001), female (*P* = 0.01), have CKD III or more advanced (*P* \< 0.001) and higher burden of comorbidities as indicated by higher Charlson comorbidity index (low dose: 5.52 ± 3.75 vs. high dose: 4.17 ± 3.47, *P* \< 0.001). Among rivaroxaban patients, low dose was more frequently prescribed to patients over 75 years (*P* \< 0.001), females (*P* = 0.03), patients with CKD III or more advanced (*P* \< 0.001) and patients with higher comorbidity burden (low dose: 5.05 ± 3.65 vs. high dose: 3.71 ± 3.34, *P* \< 0.001). Table 1Characteristics of patients taking standard (150 mg) or reduced (75 mg) dose dabigatranReduced dose (75 mg twice daily)Standard Dose (150 mg twice daily)*P*-valueTotal number of patients14556580Age Category, years*\< 0.001* 65--697.1%18.0% 70 to 7413.7%26.8% 75 to 7918.8%25.4% 80 to 8426.0%18.1% 85 to 8916.8%7.1% 90 or over17.5%4.7%Sex*\< 0.001* Female56.3%47.9% Male43.7%52.1%Race Category*\< 0.001* White84.1%87.5% Black10.2%6.9% Hispanic2.5%1.7% Asian1.4%0.6% Other1.9%3.2% Smoking14.0%16.7%0.01 Alcohol use2.0%2.3%\< 0.001Weight Category (based on ICD-9 and ICD-10 codes for BMI Category)*\< 0.001* Under-Weight1.2%0.6% Healthy or Overweight10.1%8.0% Obese or Severe Obese20.1%23.9% Not available68.5%67.5%Comorbid Conditions Prior Stroke26.8%24.4%0.06 Prior major bleeding from Diagnosis26.7%24.5%0.07 Gastrointestinal bleeding013.0%0.24 Cerebral bleeding00.8%0.7 Diabetes50.7%48.9%0.2 Prior AMI8.0%5.2%\< 0.001 Liver Disease3.4%2.6%0.13 Heart Failure48.6%31.3%\< 0.001 Hypertension96.0%93.4%\< 0.001 Ischemic cardiomyopathy55.5%48.0%\< 0.001 Pulmonary16.6%11.4%\< 0.001 COPD36.4%31.8%\< 0.001 Transfusion from Procedure3.8%2.7%0.02 Revascularization17.3%15.0%0.03 Implantable Devices16.9%13.8%0.002 Valve Disease44.7%40.3%0.002Renal Disease (ICD-9 and ICD-10 codes)\< 0.001 None or Mild (Stage I, II)53.4%81.7% Moderate (Stage III)36.0%16.5% Severe (Stage IV, V)10.6%1.7%Concurrent Drugs (+/− 90 days of initiating DOAC) SSRI/SNRI33.5%31.0%0.05 Strong and moderate P-GP inhibitors21.4%22.7%0.28 P-GP inducers16.4%18.8%0.03 Strong P-GP and CYP3A4 dual inhibitors22.7%22.5%0.8 P-GP and CYP3A4 inducers16.4%18.8%0.03 ACE inhibitors70.1%68.0%0.12 Warfarin20.8%25.0%\< 0.001 Angiotensin receptor blockers41.0%39.3%0.2 Beta blockers92.1%89.1%\< 0.001 Calcium channel blockers66.8%63.8%0.03 Digoxin31.1%29.4%0.2 Proton pump inhibitors60.5%56.4%0.004 NSAIDs49.6%51.2%0.29 Antiplatelets32.0%26.5%\< 0.001 Insulin17.0%12.9%\< 0.001 Statins79.6%79.4%0.86 Antiarrhythmics47.3%48.0%0.6Estimated Glomerular Filtration rate (ml/min/1.73 m2)*\< 0.001*  \< 3012.3%2.5% 30--6062.2%45.8% 60--9023.8%46.0%\> = 901.8%5.7%CCI(Charlson Comorbodity Index), mean (standard deviation)5.52 (3.75)4.17(3.47)\< 0.001Abbreviations: *ACE* Angiotensin converting enzyme, *AMI* Acute myocardial infarction, *COPD* Chronic obstructive pulmonary disease, *ICD* International classification of diseases, *NSAIDS* Non-steroidal antiinflammatory drugs, *P-GP* P-glycoprotein, *CYP* CytochromeTable 2Characteristics of patients taking standard (20 mg) or reduced (15 mg) dose rivaroxabanReduced Dose\
(15 mg daily)Standard Dose\
(20 mg daily)*P*-valueTotal number of patients646713,245Age Category, years*\< 0.001* 65--697.9%18.2% 70 to 7414.8%29.0% 75 to 7920.7%25.6% 80 to 8425.4%17.0% 85 to 8919.8%7.8% 90 or over11.4%2.4%Sex*\< 0.001* Female57.1%46.2% Male42.9%53.8%Race Category*\< 0.001* White85.2%85.8% Black9.0%8.0% Hispanic2.2%1.6% Asian0.8%0.8% Other2.8%3.8% Smoking20.2%22.8%\< 0.001 Alcohol2.3%3.2%\< 0.001Weight Category (based on ICD-9 and ICD-10 codes for BMI Category)*\< 0.001* Under-Weight2.3%1.3% Healthy or Overweight19.1%14.3% Obese or Severe Obese26.2%31.2% Not available52.4%53.2%Comorbid Conditions Prior Stroke28.2%22.4%\< 0.001 Prior major bleeding from Diagnosis26.6%23.9%\< 0.001 Gastrointestinal bleeding15.2%13.5%0.002 Cerebral bleeding1.3%0.8%\< 0.001 Diabetes51.0%47.7%\< 0.001 Prior AMI9.0%5.7%\< 0.001 Liver Disease2.9%3.1%0.35 Heart Failure35.6%24.3%\< 0.001 Hypertension94.6%92.1%\< 0.001 Ischemic cardiomyopathy47.7%40.2%\< 0.001 Pulmonary15.9%11.1%\< 0.001 COPD36.3%31.4%\< 0.001 Transfusion from Procedure5.0%2.3%\< 0.001 Revascularization16.5%13.7%\< 0.001 Implantable Devices16.7%12.5%\< 0.001 Valve Disease40.6%36.4%0.002Renal Disease (ICD-9 and ICD-10 codes)\< 0.001 None or Mild (Stage I, II)54.8%83.9% Moderate (Stage III)37.5%14.5% Severe (Stage IV, V)7.7%1.5%Concurrent Drugs (+/− 90 days of initiating DOAC) SSRI/SNRI33.7%29.1%\< 0.001 Strong and moderate P-GP inhibitors18.3%18.5%0.63 P-GP inducers18.5%16.5%\< 0.001 Strong P-GP and CYP3A4 dual inhibitors22.7%20.8%0.002 P-GP and CYP3A4 inducers18.5%16.5%\< 0.001 ACE inhibitors67.4%64.3%\< 0.001 Warfarin15.0%16.1%0.045 Angiotensin receptor blockers40.0%36.7%\< 0.001 Beta blockers88.1%86.5%0.015 Calcium channel blockers64.5%59.4%\< 0.001 Digoxin23.1%20.8%\< 0.001 Proton pump inhibitors58.3%52.3%\< 0.001 NSAIDs52.9%50.1%\< 0.001 Antiplatelets30.2%24.3%\< 0.001 Insulin14.3%10.8%\< 0.001 Statins79.3%77.6%0.006 Antiarrhythmics40.4%43.1%\< 0.001Estimated Glomerular Filtration rate (ml/min/1.73 m2)\< 0.001  \< 307.5%1.3% 30--6061.1%35.2% 60--9028.8%56.7%  \> =902.6%6.8%CCI(Charlson Comorbodity Index), mean (standard deviation)5.05(3.65)3.71(3.34)\< 0.001Abbreviations: *ACE* Angiotensin converting enzyme, *AMI* Acute myocardial infarction, *COPD* Chronic obstructive pulmonary disease, *ICD* International classification of diseases, *NSAIDS* Non-steroidal antiinflammatory drugs, *P-GP* P-glycoprotein, *CYP* Cytochrome

As shown on Tables [3](#Tab3){ref-type="table"}, [4](#Tab4){ref-type="table"}, [5](#Tab5){ref-type="table"} and [6](#Tab6){ref-type="table"}, 1401 (17.4%) and 7820 (39.7%) patients who received dabigatran and rivaroxaban met criteria for low dose, respectively. Of those, 959 (68.5%) and 3904 (49.9%) received standard dose of dabigatran and rivaroxaban respectively. In contrast, 1013 (15.3%) and 2551 (21.5%) of patients eligible for standard dose dabigatran and rivaroxaban received low dose**.** Patients older than 75 years, females, African Americans, and patients with history of major bleeding or heart failure were more likely to receive lower than recommended dose of dabigatran or rivaroxaban (Tables [3](#Tab3){ref-type="table"}, [4](#Tab4){ref-type="table"}, [5](#Tab5){ref-type="table"} and [6](#Tab6){ref-type="table"}). Conversely, patients eligible for low dose dabigatran or rivaroxaban that received standard dose were more likely younger with lower rates of advanced CKD. Table 3Bivariable associations between low dose dabigatran eligible patients' characteristics on low or standard dose of dabigatranLow dose eligible that received low dose Dabigatran\
(*n* = 442)Low dose eligible that received standard dose Dabigatran\
(*n* = 959)*P* valueBefore Matching\
Standardized DifferenceAfter Matching\
(*N* = 366 vs 366)\
Standardized DifferenceYear0.001 2010--201257.7%69.3%0.2440.228 201316.1%10.3%0.1700.289 201410.9%8.1%0.0930.047 20157.7%6.5%0.0480 2016--20177.7%5.7%0.0780.011Region0.1 Midwest15.4%12.4%0.0860.008 Northeast0.5%1.4%0.0960.141 South73.3%76.7%0.0800 West10.9%9.5%0.0450.035Age Category\< 0.001 65--697.9%14.0%0.1950 70 to 7416.5%24.2%0.1920 75 to 7918.6%28.5%0.2350 80 to 8425.1%19.3%0.1400 85 to 8913.1%7.8%0.1740 90 or over18.8%6.3%0.3850Sex0.2 Female57.9%54.3%0.0720 Male42.1%45.7% Race Category White84.2%85.0%0.0230 Black10.4%8.9%0.0520 Hispanic2.5%2.4%0.0060 Other0Smoking0.04 Yes11.5%15.7%0.1230.055 No88.5%84.3%Weight Category (based on ICD-9 and ICD-10 codes for BMI Category)0.02 Underweight1.6%0.6%0.0920 Healthy or Overweight8.6%6.3%0.0890.062 Obese or Severe Obese20.4%26.3%0.1400.013 Others69.5%66.8%0.0560.024Comorbid Conditions Prior Stroke26.7%27.4%0.80.0160.042 Prior major bleeding29.0%28.2%0.80.0180.006 Diabetes55.0%54.0%0.70.0190.077 Prior AMI10.6%6.2%0.0030.1620.147 Liver Disease2.9%3.2%0.80.0170 Heart Failure56.8%40.7%\< 0.0010.3270.265 Hypertension98.2%96.1%0.040.1240.082 Ischemic cardiomyopathy60.4%57.2%0.30.0640.089 Pulmonary18.8%13.3%0.0080.1480.066 COPD37.8%36.2%0.60.0330.034 Transfusion from Procedure5.4%4.3%0.30.0540.051 Revascularization18.6%17.8%0.70.0190.043 Implantable Devices20.1%17.5%0.20.0670 Valve Disease45.9%42.0%0.20.0790.099Concurrent Drugs (+/− 90 days of initiating DOAC) SSRI/SNRI32.6%36.5%0.150.0830.023 Strong and moderate p-gp inhibitors53.5%79.9%\< 0.0010.5800.068 Warfarin22.6%31.0%0.0010.1890.153 Strong p-gp and cyp3a4 dual inhibitors35.7%47.5%\< 0.0010.2410.089 ACE inhibitors74.0%72.7%0.60.0290.044 Angiotensin receptor blockers46.6%45.9%0.80.0150.066 Beta blockers95.2%92.9%0.090.0990.165 Calcium channel blockers69.7%67.5%0.40.0480.098 Digoxin28.7%33.8%0.060.1090.083 Proton pump inhibitors64.7%63.2%0.60.0320.119 NSAIDs52.7%55.4%0.40.0530.055 Antiplatelets35.3%31.3%0.130.0850.099 Insulin22.9%17.6%0.020.1300.206 Statins80.8%83.3%0.240.0660.007Renal Disease Moderate (GFR 30--60 ml/min/1.73 m2)45.7%74.9%\< 0.0010.62450.0439 Severe(GFR \< 30 ml/min/1.73 m2)54.3%25.1%Abbreviations: *ACE* Angiotensin converting enzyme, *AMI* Acute myocardial infarction, *COPD* Chronic obstructive pulmonary disease, *ICD* International classification of diseases, *NSAIDS* Non-steroidal antiinflammatory drugs, *P-GP* P-glycoprotein, *CYP* CytochromeTable 4Bivariable associations between standard dose dabigatran eligible patients' characteristics on low or standard dose of dabigatranStandard dose eligible that received low dose Dabigatran (*n* = 1013)Standard dose eligible that received standard dose Dabigatran (*n* = 5621)*P* valueBefore Matching\
Standardized DifferenceAfter Matching (*N* = 1001 vs 1001)\
Standardized DifferenceYear\< 0.001 2010--1250.0%55.7%0.1160.198 201318.6%13.6%0.1370.174 201411.6%11.4%0.0080.032 201510.9%10.1%0.0260.047 2016--179.0%9.3%0.0090.040Region0.8 Midwest12.3%12.9%0.0170.024 Northeast1.7%1.5%0.0180.016 South73.7%74.3%0.0120.009 West12.2%11.4%0.0270.006Age Category\< 0.001 65--696.7%18.7%0.3650 70 to 7412.5%27.3%0.37550 75 to 7919.0%24.9%0.1430 80 to 8426.4%17.9%0.2060 85 to 8918.5%6.9%0.3510 90 or over17.0%4.4%0.4150Sex\< 0.001 Female55.6%46.8%0.1760 Male44.4%53.2%Race Category\< 0.001 White84.0%87.9%0.1130 Black10.1%6.6%0.1260 Hispanic2.5%1.6%0.0590 Asian1.2%0.6%0.0660 Other2.3%3.3%0.0600 Smoker15.0%16.8%0.150.0490.037Weight Category (based on ICD-9/ ICD-10 codes for BMI)0.003 Under Weight1.1%0.6%0.0570.031 Healthy or Overweight10.8%8.3%0.0820.013 Obese or Severe Obese20.0%23.4%0.0840.054 Others68.1%67.6%0.0100.061Comorbid Conditions Prior Stroke26.9%23.9%0.040.0670.011 Prior Major Bleeding25.8%23.9%0.20.0440.042 Diabetes48.9%48.0%0.60.0180.066 Prior AMI6.9%5.0%0.010.0820.103 Liver Disease3.6%2.5%0.070.0590.126 Heart Failure45.0%29.7%\< 0.0010.3200.274 Hypertension95.1%93.0%0.010.0890.088 Ischemic Cardiomyopathy53.4%46.4%\< 0.0010.1400.110 Pulmonary Circulatory Disease15.6%11.0%\< 0.0010.1350.083 COPD35.7%31.0%0.0030.10.115 Blood Transfusion3.2%2.4%0.180.0440 Revascularization16.8%14.5%0.050.0630.075 Implantable cardiac device15.5%13.1%0.040.0680.011 Valve Disease44.1%40.0%0.0150.0830.024Concurrent Drugs (+/− 90 days of initiating DOAC) SSRI/SNRI34.0%30.0%0.010.0850.126 Strong and moderate p-gp inhibitors7.3%12.9%\< 0.0010.1880.135 Warfarin19.9%24.0%0.0040.0990.237 Strong p-gp and cyp3a4 dual inhibitors17.0%18.2%0.30.03250.032 ACE inhibitors68.4%67.2%0.450.02570.081 Angiotensin receptor blockers38.6%38.1%0.80.00940.010 Beta blockers90.7%88.4%0.030.07590.108 Calcium channel blockers65.5%63.2%0.150.04880.040 Digoxin32.1%28.7%0.030.07410.002 Proton pump inhibitors58.7%55.2%0.040.07070.008 NSAIDs48.3%50.4%0.20.04330.04 Antiplatelets30.5%25.7%0.00150.10640.093 Insulin14.5%12.1%0.030.0720.137 Statins79.1%78.7%0.80.0090.079Renal Disease\< 0.001 None or Mild33.6%57.2%0.4890.255 Moderate (GFR 30--60 ml/min/1.73 m2)66.4%42.8%Severe (GFR \< 30 ml/min/1.73 m2)0.0%0.0%Abbreviations: *ACE* Angiotensin converting enzyme, *AMI* Acute myocardial infarction, *COPD* Chronic obstructive pulmonary disease, *ICD* International classification of diseases, *NSAIDS* Non-steroidal antiinflammatory drugs, *P-GP* P-glycoprotein, *CYP* CytochromeTable 5Bivariable associations between low dose rivaroxaban eligible patients' characteristics on low or standard dose of rivaroxabanLow dose eligible that received low dose Rivaroxaban\
(*n* = 3916)Low dose eligible that received standard dose Rivaroxaban (*n* = 3904)*P* valueBefore Matching\
Standardized DifferenceAfter Matching\
(*N* = 2703 vs 2703)\
Standardized DifferenceYear0.2 2010--20127.2%6.7%0.0210.028 201318.3%17.6%0.0170.0308 201423.0%23.0%0.0020.016 201522.9%21.8%0.0240.003 2016--201728.6%30.9%0.0500.058Region0.04 Midwest15.2%13.0%0.0640.084 Northeast1.2%1.1%0.0090.016 South73.0%75.0%0.0440.028 West10.5%10.9%0.0130.061Age Category\< 0.001 65--697.5%14.5%0.2250 70 to 7414.0%26.0%0.3020 75 to 7920.1%25.8%0.1350 80 to 8425.5%19.7%0.1390 85 to 8920.5%10.1%0.2910 90 or over12.4%3.9%0.3110Sex0.0008 Female56.0%52.3%0.0760 Male44.0%47.7%Race Category0.7 White84.5%83.4%0.0310 Black10.2%10.7%0.0170 Hispanic2.0%2.2%0.0110 Asian0.7%0.8%0.0150 Other2.7%3.0%0.0190 Smoker19.6%22.5%0.0010.0730.033Weight Category (ICD9/ICD-10 codes for BMI)\< 0.0001 Under Weight1.9%1.2%0.0530.025 Healthy or Overweight18.4%16.1%0.0620.008 Obese or Severe Obese28.9%35.4%0.1390.079 Others50.8%47.3%0.0700.062Comorbid Conditions Prior Stroke29.1%25.1%\< 0.0010.0890.051 Prior major bleeding27.6%28.0%0.60.0110.026 Diabetes55.9%57.2%0.20.0270.021 Prior AMI10.4%6.7%\< 0.0010.1320.119 Liver Disease3.2%3.5%0.40.0190.017 Heart Failure41.2%31.6%\< 0.0010.2010.151 Hypertension96.8%95.3%\< 0.0010.0760.030 Cardiomyopathy50.4%44.6%\< 0.0010.1150.100 Pulmonary Circulatory Dis17.2%14.2%\< 0.0010.0820.021 COPD38.5%37.0%0.170.0310.054 Prior Blood Transfusion5.8%3.5%\< 0.0010.1070.083 Revascularization17.7%15.4%0.0070.0610.079 Implantable Cardiac Device18.3%14.8%\< 0.0010.0940.078 Valve Disease42.2%38.1%\< 0.0010.0840.064Concurrent Drugs (+/− 90 days of initiating DOAC) SSRI/SNRI34.0%33.3%0.50.0140.034 Strong and moderate p-gp inhibitors19.9%24.5%\< 0.0010.1100.012 Warfarin16.1%19.6%\< 0.0010.0920.124 Pgp inducers17.9%18.0%0.90.0030.018 Strong p-gp and cyp3a4 dual inhibitors26.1%35.1%\< 0.0010.1940.009 P-gp and cyp3a4 inducers17.9%18.1%0.90.0030.017 Ace inhibitors70.6%69.6%0.340.0220.025 Angiotensin receptor blockers43.9%43.8%0.860.0040.004 Beta blockers89.7%89.0%0.320.0230.019 Calcium channel blockers67.6%64.4%=0.0030.0670.026 Digoxin23.0%23.3%0.70.0080.003 Proton pump inhibitors59.6%59.2%0.70.0080.026 NSAIDS52.6%53.3%0.50.0150.022 Antiplatelets31.8%28.4%0.0010.0740.067 Insulin18.0%17.1%0.270.0250.087 Statins81.8%81.6%0.790.0060.024Renal Disease None or mild3.6%17.1%\< 0.00010.4520.058 Moderate (GFR 30--60 ml/min/1.73 m2)83.3%77.4%0.1490.039 Severe(GFR \< 30 ml/min/1.73 m2)13.1%5.5%0.2620.002Abbreviations: *ACE* Angiotensin converting enzyme, *AMI* Acute myocardial infarction, *COPD* Chronic obstructive pulmonary disease, *ICD* International classification of diseases, *NSAIDS* Non-steroidal antiinflammatory drugs, *P-GP* P-glycoprotein, *CYP* CytochromeTable 6Bivariable associations between standard dose rivaroxaban eligible patients' characteristics on low or standard dose of rivaroxabanStandard dose eligible that received low dose Rivaroxaban (*n* = 2551)Standard dose eligible that received standard dose Rivaroxaban (*n* = 9341)*P* valueBefore Matching Standardized DifferenceAfter Matching\
(*N* = 2397 vs 2397)\
Standardized DifferenceYear*0.06* 2010--20128.2%7.1%0.04390.0031 201317.9%17.1%0.02040.0098 201423.8%22.7%0.02560.0248 201521.4%22.7%0.03120.0051 2016--201728.7%30.4%0.03790.0284Region*0.12* Midwest15.1%14.4%0.01780.1713 Northeast1.1%1.3%0.02290.1515 South73.1%72.0%0.02540.2038 West10.8%12.3%0.04760.0186Age Category*\< 0.0001* 65--698.5%19.7%0.32660 70 to 7415.9%30.3%0.34530 75 to 7921.6%25.5%0.09160 80 to 8425.3%15.9%0.23370 85 to 8918.8%6.9%0.36220 90 or over9.8%1.7%0.35440Sex*\< 0.0001* Female58.7%43.7%0.30440 Male41.3%56.3%Race Category*\< 0.0001* White86.2%86.8%0.01640 Black7.3%6.9%0.01440 Hispanic2.4%1.3%0.08130 Asian1.1%0.8%0.03040 Other3.0%4.2%0.0650 Smoker21.1%23.0%0.050.0440.003Weight Category (based on ICD-9/ICD-10 codes for BMI)*\< 0.0001* Under2.9%1.4%0.10380.0682 Healthy or Overweight20.1%13.6%0.17370.2328 Obese or Severe Obese22.1%29.4%0.16840.0561 Others55.0%55.6%0.01260.2406Comorbid Conditions Prior Stroke26.9%21.3%\< 0.0010.12950 Prior major bleeding25.2%22.2%0.0010.0710 Diabetes43.4%43.8%0.760.00690.1063 Prior AMI7.0%5.3%0.0010.07010 Liver Disease2.4%2.9%0.140.03370.0139 Heart Failure27.0%21.3%\< 0.0010.13390 Hypertension91.2%90.8%0.570.01280.0474 Cardiomyopathy43.5%38.3%\< 0.0010.10630.1134 Pulmonary Circulatory dis13.9%9.8%\< 0.0010.12770.0414 COPD33.0%29.1%\< 0.0010.08460.0972 Prior blood transfusion3.7%1.8%\< 0.0010.11730.0855 Revascularization14.7%13.0%0.020.04950.08 Implantable Devices14.1%11.6%\< 0.0010.07660.0553 Valve Disease38.1%35.7%0.020.0510.0347Concurrent Drugs (+/− 90 days of initiating DOAC) SSRI/SNRI33.3%27.4%\< 0.0010.12890.0682 Strong and moderate p-gp inhibitors15.7%16.1%0.670.00960 Warfarin13.2%14.6%0.080.03910.1199 Pgp inducers19.5%15.8%\< 0.0010.0970 Strong p-gp and cyp3a4 dual inhibitors17.3%14.8%0.0020.0690.0232 P-gp and cyp3a4 inducers19.5%15.8%\< 0.0010.0970 Ace inhibitors62.4%62.1%0.770.00660.006 Angiotensin receptor blockers33.8%33.8%0.980.00050.0222 Beta blockers85.7%85.4%0.740.00750.042 Calcium channel blockers59.6%57.3%0.030.04750.0179 Digoxin23.4%19.8%\<.0010.08920.0403 Proton pump inhibitors56.2%49.5%\< 0.0010.13560.0753 NSAIDS53.2%48.7%\< 0.0010.0910.133 Antiplatelets27.9%22.5%\< 0.0010.12290.0785 Insulin8.5%8.2%0.540.01360.0247 Statins75.4%75.9%0.60.01140.0608Renal Disease None or mild100.0%100.0%Not available due to perfect matchModerate (GFR 30--60 ml/min/1.73 m2)Severe(GFR \< 30 ml/min/1.73 m2)Abbreviations: *ACE* Angiotensin converting enzyme, *AMI* Acute myocardial infarction, *COPD* Chronic obstructive pulmonary disease, *ICD* International classification of diseases, *NSAIDS* Non-steroidal antiinflammatory drugs, *P-GP* P-glycoprotein, *CYP* Cytochrome

Mean follow-up for patients eligible for low dose dabigatran, standard dose dabigatran, low dose rivaroxaban, and standard dose rivaroxaban were 13.9, 15.1, 10.1, and 12.3 months, respectively.

Outcomes {#Sec10}
--------

### Stroke {#Sec11}

The absolute event rates and event rates/year for ischemic stroke in each dosing category are presented in Table [7](#Tab7){ref-type="table"}. Before adjustment for patient characteristics or propensity-match analysis, use of low dose dabigatran among patients eligible for standard dose dabigatran did not affect ischemic stroke risk. Among those eligible for standard dose rivaroxaban but receiving low dose, no significantly different risk of ischemic stroke was found. Among patients eligible for low dose dabigatran who received standard dose, we did not identify any relationship to ischemic stroke risk (Table [7](#Tab7){ref-type="table"}). Also, among patients eligible for low dose rivaroxaban, use of standard dose rivaroxaban was not associated with increased risk of ischemic stroke. After propensity matching, we found no difference in risk of ischemic stroke in 732 patients eligible for low dose dabigatran who received low dose compared to 732 matched patients eligible for low dose dabigatran who received standard dose, or among propensity-matched patients eligible for standard dose dabigatran who received either standard dose (*n* = 1960) or low dose (*n* = 1960). Similarly, analysis of propensity matched samples of patients eligible for low dose rivaroxaban (5328 on low dose and 5328 on standard dose) or patients eligible for standard dose rivaroxaban (4500 on standard dose and 4500 on low dose) found no significant association of dose to risk of ischemic stroke (Table [7](#Tab7){ref-type="table"}). Table 7Hazard ratios (95% Confidence Intervals) of Outcomes in Matched Cohorts of Dabigatran and Rivaroxaban low and standard doses in Non-Valvular Atrial FibrillationPatients Eligible for low dose but taking standard dose vs. those taking low dosePatients Eligible for Standard dose but taking low dose vs. those taking dose standard doseReceived Low Dose\
*Events (Events/year)*Received Standard Dose\
*Events (Events/year)*95% Confidence Interval, *p*-valueReceived Low Dose\
*Events (Events/year)*Received Standard Dose\
*Events (Events/year)*95% Confidence Interval, *p*-valueIschemic Stroke Dabigatran*Unadjusted*25 (0.059)57 (0.043)0.77 (0.47--1.26; *p* = 0.3)59 (0.051)319 (0.042)1.2 (0.92--1.6, *P* = 0.17)*Propensity Matched*22 (0.059)28 (0.061)1.13 (0.63--2; *p* = 0.69)55 (0.049)88 (0.071)0.74 (0.53--1.04; *p* = 0.08) Rivaroxaban*Unadjusted*176 (0.057)161 (0.043)0.87 (0.7--1.1; *p* = 0.2)89 (0.040)256 (0.026)*1.36 (1.07--1.7, P = 0.01)Propensity Matched*103 (0.048)128 (0.053)1.24 (0.96--1.6; *p* = 0.1)78 (0.040)73 (0.030)1.13 (0.83--1.56, *P* = 0.43)Major Bleeding Dabigatran*Unadjusted*62 (0.1456)124 (0.093)*0.69 (0.51--0.94; p = 0.02)*82 (0.071)393 (0.051)*1.35 (1.06--1.7, p = 0.01)Propensity Matched*46 (0.1228)58 (0.1258)1.07 (0.7--1.58 *P* = 0.75)78 (0.069)92 (0.075)1.01 (0.74--1.37, *P* = 0.97) Rivaroxaban*Unadjusted*307 (0.099)294 (0.079)0.95 (0.8--1.1, *P* = 0.5)147 (0.067)426 (0.043)*1.35 (1.12--1.6, P = 0.001)Propensity Matched*197 (0.091)216 (0.089)1.12 (0.92--1.35, *P* = 0.26)131 (0.068)116 (0.048)1.2 (0.93--1.53, *P* = 0.21)GI Hemorrhage Dabigatran*Unadjusted*46 (0.108)100(0.075)0.75 (0.5--1.07, *P* = 0.1)67 (0.058)292 (0.038)*1.47 (1.13--1.9, P = 0005)Propensity Matched*33 (0.088)45 (0.098)1.16 (0.74--1.82, *P* = 0.53)63 (0.056)68 (0.055)1.08 (0.77--1.53, *P* = 0.66) Rivaroxaban*Unadjusted*243 (0.078)227 (0.061)0.93 (0.78--1.1, *P* = 0.4)111 (0.050)341 (0.034)*1.28 (1.04--1.6, P = 0.02)Propensity Matched*158 (0.073)166 (0.069)1.07 (0.86--1.32, *P* = 0.5)97 (0.050)96 (0.040)1.08 (0.82--1.43, *P* = 0.58)Intracranial Hemorrhage Dabigatran*Unadjusted*\< 11\< 11*0.33 (0.12--0.9; p = 0.03)*\< 1152 (0.007)0.77 (0.33--1.8; *p* = 0.54)*Propensity Matched*\< 11\< 110.63 (0.2--1.99; *p* = 0.43)\< 1112(0.009)0.58 (0.22--1.54; *p* = 0.27) Rivaroxaban*Unadjusted*25 (0.008)26 (0.007)0.99 (0.57--1.7; *p* = 0.96)13 (0.006)38 (0.004)1.33 (0.7--2.5; *p* = 0.37)*Propensity Matched*17 (0.008)22 (0.009)1.26 (0.67--2.38; *p* = 0.47)12 (0.006)\< 111.57 (0.64--3.84; *p* = 0.32)

### Major bleeding {#Sec12}

The absolute event rates and event rates/year for bleeding complications in each dosing category are presented in Table [7](#Tab7){ref-type="table"}. Among patients on dabigatran who met criteria for standard dose, use of low dose was associated with significantly higher risk of any major bleeding (HR = 1.44; 95% CI 1.14--1.8, *P* = 0.002, Table [7](#Tab7){ref-type="table"}), and higher risk of GI bleeding (HR 1.48, 95% CI 1,08--2, *P* = 0.016) but not intracranial bleeding compared with patients on standard doses of dabigatran. A similar pattern of increased major bleeding risk (HR 1.34, 95% CI 1.11--1.6, *P* = 0.002) was identified among patients on rivaroxaban who met criteria for standard dose but received low dose, along with a trend towards increased risk of GI bleeding (HR 1.26, 95% CI 0.99--1.6, *P* = 0.06) but not intracranial bleeding.

In patients who met criteria for low dose dabigatran, there was lower risk of major bleeding (HR = 0.59; 95% CI 0.43--0.8, *P* \< 0.001, Table [7](#Tab7){ref-type="table"}) and intracranial bleeding (HR = 0.33; 95% CI 0.12--0.9, *P* = 0.03, Table [7](#Tab7){ref-type="table"}) but not GI bleeding in patients who received standard compared to low dose dabigatran. Among patients who met criteria for low dose rivaroxaban, there was lower risk of GI bleeding (HR = 0.79; 95% CI 0.64--0.98, *P* = 0.03, Table [7](#Tab7){ref-type="table"}) without differences in the risk of major, and intracranial bleeding. After controlling for patient characteristics in propensity-matched samples, we did not find any association of off-label use of low dose or standard dose and the risk of any bleeding events for either dabigatran or rivaroxaban.

### Sensitivity analysis {#Sec13}

We performed sensitivity analysis among patients with dose adjustments based on valid GFR measurements only and not based on pharmacologic interactions. The propensity matched analysis showed that standard dose dabigatran is associated with higher risk of stroke among patients eligible for low dose according to GFR (HR 2.6, 95% CI 1.03--6.7; *p* = 0.04). The analysis did not suggest any other significant differences in stroke and bleeding risks between off-label and standard dosing of dabigatran and rivaroxaban. The results are presented in Additional file [2](#MOESM2){ref-type="media"}: Table S2.

Discussion {#Sec14}
==========

The findings of this retrospective cohort analysis of Medicare beneficiaries with AF treated with dabigatran or rivaroxaban between 2010 and 2016 can be summarized as follows: i) among patients on dabigatran or rivaroxaban who met criteria for low dose, the majority received standard dose; ii) among patients on dabigatran or rivaroxaban who met criteria for standard dose, less than one fourth received the low dose; iii) older age, female sex, black race, bleeding history, and heart failure were associated with receipt of lower than recommended dose for patients receiving dabigatran or rivaroxaban; iv) unadjusted analysis suggested that in patients receiving lower dose than recommended, the risk of any major bleeding was increased, likely reflecting higher baseline bleeding risk, while in patients receiving higher dose than recommended, the risk of bleeding was decreased; v) after risk adjusting using multivariable models or propensity-matching, off-label dosing of dabigatran or rivaroxaban was not associated with increased risk of stroke or bleeding compared to recommended dosing. An increased risk of ischemic stroke with standard dose dabigatran was found among patients eligible for low dose based on eGFR only.

The results of our analysis are in accordance with findings of previous studies which demonstrated that a significant part of AF population on DOACs receive an off-label dose \[[@CR14], [@CR15], [@CR19]\]. An updated analysis of the ORBITA-AF II registry from 2013 until 2016, including 7925 AF patients treated with DOACs, showed that 84% received DOACs at standard dose (mainly rivaroxaban and apixaban, only 451 patients on dabigatran), which was consistent with FDA labeling in 96% of cases \[ [@CR15]\]. Reduced DOAC dose was prescribed to 16% of patients, which was consistent with FDA labeling in 43%. In unadjusted analysis, under-dosing was associated with higher rates of all-cause mortality and major bleeding \[[@CR15]\]. Nevertheless, after risk- adjustment, the use of lower-than-recommended dose resulted in similar thromboembolic and bleeding risk compared to appropriately dosed DOAC use \[[@CR15]\]. Our cohort included a larger sample size than ORBITA-AF II and focused on dabigatran and rivaroxaban as opposed to apixaban and rivaroxaban in ORBITA-AF II. Another methodological difference is the use of calculated creatinine clearance with the Cockcroft-Gault formula instead of the MDRD or the CKD-EPI equations for eGFR calculation that we applied. Although in clinical practice, eGFR by MDRD or CKD-EPI is more commonly used than calculated creatinine clearance, discordances in dabigatran and rivaroxaban doses may occur in up to 30% of elderly patients with creatinine clearance \< 60 ml/min \[ [@CR19]\]. Despite these methodological differences both our analysis and the previous report from the ORBITA-AF II registry suggest that among patients on dabigatran or rivaroxaban who met criteria for low dose, the majority received standard dose. Moreover, unadjusted analysis suggested that in patients receiving lower dose than recommended, the risk of any major bleeding was increased. In both analyses, propensity matching did not reveal any significant differences in stroke and bleeding.

Yao et al.^19^ previously evaluated potential over- and under- dosing of DOACs based only on renal indication for dose reduction using the data for privately insured and Medicare Advantage enrollees. Like our study, Yao et al. found no significant relationship between risk of stroke or bleeding and dose in dabigatran or rivaroxaban-treated patients with renal indication for dose reduction. However, in aggregate analyses of patients taking dabigatran, rivaroxaban or apixaban with renal indication for low dose, patients had significantly higher bleeding risk if they received standard dose. Consistent with our study, Yao et al. also found no statistically significant relationship between dose reduction and risk of stroke or bleeding in the dabigatran- or rivaroxaban-treated patients who did not have a renal indication for low dose. In contrast to our study, Yao et al. evaluated renal indications for dose reductions only, and did not consider use of p-gp inhibitors or dual p-gp and CYP3A4 inhibitors in assessing dosing criteria.

In aggregate our findings demonstrate that decisions by healthcare providers about DOAC dosing may be based on patient clinical conditions not reflected in FDA dosing recommendations. Our analysis suggests that patients deemed by providers to be at higher bleeding risk may have received low dose DOACs even though FDA criteria suggest that they qualified for standard dose. It is noteworthy that our unadjusted analyses found higher risk of bleeding in patients who met criteria for standard dose rivaroxaban or dabigatran but received low dose, suggesting that the perception of higher bleeding risk by physicians was warranted, and may point to important patient characteristics not reflected in FDA criteria. Similarly, patients qualifying for low dose may have been prescribed standard doses if providers deemed their bleeding risk to be low.

DOAC-specific factors should predominantly affect dosing decisions. Renal function is the main indicator for low dose dabigatran and rivaroxaban. Nearly \~ 80% of ingested dabigatran is metabolized by the kidney, while \~ 30% of rivaroxaban is metabolized by the kidney. With chronic kidney disease, the half-lives of these medications are extended, leading to potentially high plasma concentrations of the medications and increased bleeding risk \[[@CR20], [@CR21]\]. DOAC dose adjustments based on renal function therefore reflect the increased bleeding risk in patients with compromised renal function. Several drug interactions also affect dosing of DOACs. Dabigatran is a substrate for P-glycoprotein. Concomitant use of dabigatran with P-gp inducers such as rifampin reduces the anticoagulant effect of dabigatran and should be avoided whereas use of dabigatran with P-gp inhibitors (eg, ketoconazole, dronedarone) in patients with renal disease may increase the anticoagulant effect, hence dose adjustment is required. Combined P-gp and CYP3A4 inhibitors (ketoconazole, protease inhibitors) increase the anticoagulant effects of rivaroxaban and should not be used concomitantly with rivaroxaban. In our analysis, we found a significant percentage of patients on medications interfering with the metabolism of dabigatran and rivaroxaban. Notably, receipt of standard dose dabigatran among patients qualifying for low dose dabigatran due to eGFR 30--60 ml/min with concomitant use of a p-gp inhibitor was particularly common, suggesting that some providers may not recognize the potential interaction. We also note, however, that our pharmacy data only permit evaluation of prescription fills, thus it is possible that some patients receiving concomitant p-gp inhibitors were instructed not to take them or switched to an alternative drug, in which case they would not meet criteria for low dose dabigatran. Other combinations that increase the risk of bleeding with DOACs are antiplatelet agents and non-steroidal anti-inflammatory drugs (NSAIDs), although no specific dosing adjustments are recommended for patients on these drugs. In our study, we found that use of prescription anti-platelet use among patients who met criteria for standard dose dabigatran or rivaroxaban was associated with a modestly higher use of low dose dabigatran and rivaroxaban. Similarly, use of low dose rivaroxaban was also more frequent among rivaroxaban patients taking NSAIDS.

Limitations {#Sec15}
-----------

An important limitation of this paper is our inability to measure GFR using the Cockcroft-Gault \[CG\] equation, which is reflected in FDA recommendations for DOAC dosage reductions. There are three commonly used equations for estimating GFR: the oldest is the CG equation, originally published in 1976, followed by the MDRD, updated MDRD, and CKD-EPI equations in 1999, 2005, and 2009, respectively \[[@CR15], [@CR16], [@CR22]\]. The MDRD and CKD-EPI equations use serum creatinine in combination with age, sex, and race to estimate GFR, while CG also uses patient weight. The use of alternative equations for dosing decisions has been the topic of considerable debate. In clinical practice, physicians rarely use the CG-estimated GFR and instead rely on the MDRD or CKD-EPI equations, which are easy to calculate and often automatically reported with serum creatinine laboratory tests. Notably, the National Kidney Disease Education Program (NKDEP) previously indicated that either the MDRD or CG equation may be used for drug dosing decisions \[[@CR23]\], while more recently, the National Institute of Diabetes and Digestive and Kidney Diseases suggested that either CKD-EPI or CG equations are appropriate for drug dosing purpose \[[@CR24]\]. In contrast, a previous review of FDA-recommended drug dosing showed that the CG equation is historically the most common renal function equation cited in drug dosing recommendations \[[@CR25]\]. As noted by Yao et al. \[[@CR26]\], it is likely that FDA drug labels historically relied on CG-estimated GFR because this method was available before the MDRD or CKD-EPI equations were developed and widely adopted, and drug dosage recommendations have not caught up to standard clinical practice with respect to assessing renal function. Nevertheless, this poses inconsistencies with clinical practice. While for most patients, GFR estimated by the MDRD or CKD-EPI equations has reasonable concordance with CG-estimated GFR, for older patients and patients with significant comorbidity, malnutrition leading to decreased muscle mass, or morbid obesity, there may be less agreement and dosing of medications based on the former may not be consistent with FDA recommendations \[ [@CR27]--[@CR29]\]. Schwartz \[[@CR30]\] found that use of the MDRD or CKD-EPI equations rather than the CG equation for estimating GFR may fail to identify 20 to 50% of patients for whom reduced dabigatran and rivaroxaban doses are recommended. Thus, our analysis likely underestimates the number of patients who qualify for low dose rivaroxaban and dabigatran if decisions are based on the CG equation, thereby underestimating the proportion of patients who are overdosed, or overestimating the proportion of patients who are underdosed, relative to FDA criteria. However, they do likely reflect dosing decisions based on GFR estimates typically used in clinical practice.

Other potential limitations of this study should also be considered. First, due to the observational nature of the study, it is possible that unmeasured confounders could have affected our results in spite of using propensity matched analysis. Second, our analysis included patients over the age of 65 and the findings require validation in younger patients. Finally, we lacked detailed evidence on AF burden and estimation of thromboembolic risk. Strengths our study are the large sample size, the availability of laboratory results (GFR) for most patients, incorporating concomitant medication use for assessing dosing criteria, and application of risk adjustment methods including propensity-matched analyses.

Conclusion {#Sec16}
==========

The purpose of our study was to improve understanding of safety and efficacy of DOACs in AF patients receiving low or standard dosing of these medications that was inconsistent with FDA criteria. The majority of patients qualifying for low dose DOACs received standard doses and a percentage of patients qualifying for standard dosing received low dose. After adjustment for comorbidities the risk of stroke and major bleeding was not affected by use of dose inconsistent with FDA criteria. Further validation of our results is warranted especially in patients at high thromboembolic or bleeding risk.

Supplementary information
=========================

 {#Sec17}

**Additional file 1: Table S1**. ICD 9 and 10 codes of comorbidities and outcomes included in the analysis and list of medications used for dose adjustments of dabigatran and rivaroxaban. Description of Data: All ICD 9 and 10 codes included in the analysis. **Additional file 2: Table S2**. Hazard ratios (95% Confidence Intervals) of Outcomes in Cohorts of Dabigatran and Rivaroxaban low and standard doses in Non-Valvular Atrial Fibrillation. Description of Data: Hazard ratios of Outcomes from the Analysis of dose adjustments based on renal function only.

ACE

:   Angiotensin-converting-enzyme

AF

:   Atrial fibrillation

CI

:   Confidence intervals

CKD

:   Chronic kidney disease

CrCL

:   Creatinine clearance)

DOACs

:   Direct oral anticoagulants

eGFR

:   Estimated glomerular filtration rate

FDA

:   Food and Drug Administration

ICD-9-CM

:   International classification of diseases--ninth revision--clinical modification

ICH

:   Intracranial hemorrhage

MDRD

:   Modification of diet in renal disease

NKDEP

:   National Kidney Disease Education Program

P-gp

:   P-glycoprotein

P-gp-Cyp3A4

:   P-gp and cytochrome-3A4

RCT

:   Randomized controlled trials

RR

:   Relative rates

VKA

:   Vitamin K antagonist
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